Benefit Risk Analysis

A benefit risk analysis is a systematic evaluation that compares the clinical benefits of a medical intervention (such as a drug, medical device, or procedure) with its associated risks and potential harms. In the United States and the European Union, a benefit risk determination is a required part of the regulatory review of medicines and medical devices, and it informs both pre market approval decisions and post market surveillance activities.

Every medical intervention carries both potential benefits and potential risks, and the decision to approve, prescribe, or use an intervention depends on whether the expected benefits outweigh the expected harms for the intended patient population. In the United States, the FDA can approve a new drug only if it finds the drug safe and effective, and its guidance treats the demonstration of safety as showing that the benefits outweigh the risks; in the European Union, a marketing authorization for a medicine is refused if its risk benefit balance is not considered favorable. For clinicians, understanding the benefit risk profile of a treatment is essential for informed consent discussions and shared decision making with patients. For health technology assessment bodies, benefit risk analysis contributes to reimbursement and coverage decisions.

Benefit risk analysis involves several structured steps. First, the analyst identifies and characterizes the benefits (such as symptom relief, disease remission, survival improvement, or improved quality of life) and the risks (such as adverse drug reactions, surgical complications, or device failures) associated with the intervention. Each benefit and risk is described in terms of its probability of occurrence, its magnitude or severity, and its duration.

Second, the analyst assembles the evidence for each benefit and risk, drawing on clinical trial data, observational studies, post market surveillance reports, and expert judgment. The quality of evidence varies across outcomes, and the analyst should assess and report the certainty of evidence for each.

Third, the benefits and risks are weighed against each other. Several frameworks exist for this step. Qualitative approaches use structured narratives and expert judgment to compare benefits and risks. Structured frameworks organize the judgment; the FDA's Benefit Risk Framework, for example, sets out the evidence, uncertainties and conclusions across four dimensions: analysis of condition, current treatment options, benefit, and risk and risk management. Semi quantitative approaches add scoring systems or visual displays. Quantitative approaches assign numerical values to benefits and risks using metrics such as quality adjusted life years, disability adjusted life years, or multi criteria decision analysis scores, allowing direct comparison.

The conclusion of the analysis is a judgment about whether the benefit risk balance is favorable (benefits outweigh risks for the intended population), unfavorable (risks outweigh benefits), or uncertain (more evidence is needed). This conclusion may vary across patient subgroups; for example, a treatment may have a favorable benefit risk balance for patients with severe disease but an unfavorable balance for those with mild disease.

In the US, a new drug application must include an integrated summary of the benefits and risks of the drug (21 CFR 314.50(d)(5)(viii)), and a device is considered safe when its probable benefits to health outweigh any probable risks (21 CFR 860.7(d)(1)); in the EU, a medicine is not authorized if its risk benefit balance is not favorable (Directive 2001/83/EC, Article 26), and a medical device's risks must be acceptable when weighed against the benefits to the patient (Regulation (EU) 2017/745). Outside regulatory review, benefit risk analysis is recommended whenever a clinical decision involves weighing the potential benefits of an intervention against its potential harms. It is also relevant for health technology assessments, clinical guideline development, and post market safety evaluations. Researchers conducting systematic reviews that address both efficacy and safety outcomes should consider presenting their findings within a benefit risk framework.

A common error is focusing exclusively on benefits and underweighting or inadequately characterizing risks, which can lead to an overly optimistic assessment. Another mistake is failing to consider the benefit risk balance across different patient subgroups, which may differ substantially based on disease severity, comorbidities, age, or other factors.

Researchers sometimes also compare benefits and risks using incompatible metrics (for example, comparing a relative risk reduction for efficacy with an absolute risk for safety), making it difficult for decision makers to weigh them appropriately. Using consistent metrics and clear visual displays helps ensure that the comparison is meaningful. Finally, neglecting to update the benefit risk assessment as new evidence accumulates can lead to outdated conclusions, particularly in the post market setting where new safety signals may emerge.

In a hypothetical example, a regulatory agency evaluates a new anticoagulant for atrial fibrillation. Compared with no anticoagulation, the benefit risk analysis shows that the drug reduces the risk of stroke by 35% (absolute risk reduction: 1.2 strokes per 100 patient years) but increases the risk of major gastrointestinal bleeding by 50% (absolute risk increase: 0.8 major gastrointestinal bleeds per 100 patient years). The agency concludes that the benefit risk balance is favorable for patients at moderate to high stroke risk (CHA2DS2-VASc score of 2 or greater) but not clearly favorable for low risk patients (score of 0 to 1), who have a lower baseline stroke risk and so derive less absolute benefit from the same 35% relative reduction, while their bleeding risk still rises.